Oxford BioMedica PLC
LSE:OXB

Watchlist Manager
Oxford BioMedica PLC Logo
Oxford BioMedica PLC
LSE:OXB
Watchlist
Price: 644 GBX 4.04% Market Closed
Market Cap: 776m GBX

Oxford BioMedica PLC
Free Cash Flow

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Oxford BioMedica PLC
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
Oxford BioMedica PLC
LSE:OXB
Free Cash Flow
-£12m
CAGR 3-Years
29%
CAGR 5-Years
11%
CAGR 10-Years
5%
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Free Cash Flow
-$142.1m
CAGR 3-Years
-2%
CAGR 5-Years
-89%
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
Free Cash Flow
-$241.9m
CAGR 3-Years
-42%
CAGR 5-Years
-102%
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Free Cash Flow
£20.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Free Cash Flow
£48.6m
CAGR 3-Years
N/A
CAGR 5-Years
10%
CAGR 10-Years
9%
Avacta Group PLC
LSE:AVCT
Free Cash Flow
-£25.3m
CAGR 3-Years
-15%
CAGR 5-Years
-4%
CAGR 10-Years
-15%
No Stocks Found

Oxford BioMedica PLC
Glance View

Oxford Biomedica Plc is a biopharmaceutical company, which engages in the research and development of gene and cell therapy. The company is headquartered in Oxford, Oxfordshire. The firm and its subsidiaries have developed lentiviral vector delivery system, LentiVector platform, which the Company leverages to develop in vivo and ex vivo products both in-house and with partners. Its LentiVector delivery platform has created a portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, central nervous system (CNS) disorders and liver diseases. The firm's product pipeline includes OXB-302, OXB-203, OXB-204 and OXB-103 and OXB-401. The firm has also developed partnership with various pharmaceutical companies to develop potential gene and cell therapy products. Its partnered products include AXO-LENTI-PD, SAR 422459 and SAR421869.

OXB Intrinsic Value
542.73 GBX
Overvaluation 16%
Intrinsic Value
Price

See Also

What is Oxford BioMedica PLC's Free Cash Flow?
Free Cash Flow
-12m GBP

Based on the financial report for Jun 30, 2025, Oxford BioMedica PLC's Free Cash Flow amounts to -12m GBP.

What is Oxford BioMedica PLC's Free Cash Flow growth rate?
Free Cash Flow CAGR 10Y
5%

Over the last year, the Free Cash Flow growth was 83%. The average annual Free Cash Flow growth rates for Oxford BioMedica PLC have been 29% over the past three years , 11% over the past five years , and 5% over the past ten years .

Back to Top